Register Log-in Investor Type

Healthcare News

This sector includes biotechnology, pharmaceuticals, research services, home healthcare, hospitals, long-term care facilities, and medical equipment and supplies. Companies in this sector include Astra Zeneca, Pfizer and Roche Holding.

19 Dec 2017
HBM boosts dividend by 20% after stellar year

HBM Healthcare sees healthy NAV rise but remains at a deep discount

HBM Healthcare sees healthy NAV rise but remains at a deep discount Swiss-listed HBM Healthcare Investments (HBMN.S) recorded an impressive  23% rise in NAV and saw a 36% gain in its share price in the 11 months to end November, according to its latest monthly update. However, the trust’s shares currently trade at an 18.5% discount to […]

19 Dec 2017

Worldwide Healthcare maintains strong run and moves to premium

Worldwide Healthcare maintains strong run and moves to premium Despite seeing a relatively flat-to-down month in November, Worldwide Healthcare Trust (WWH) generated a 15% increase in NAV and 18% rise in its share price in the 11 month year-to-date period, comfortably beating the 9% rise in its benchmark index, according to its latest monthly factsheet. Moreover, the […]

18 Dec 2017

US analysts target Woodford Patient Capital investees

US analysts target key Woodford Patient Capital investees The Neil Woodford-managed biotech/tech investment trust, Woodford Patient Capital Trust (WPCT), is finding itself under increasing pressure, with analysts at two separate US firms calling into question its two largest investments, Prothena (15.6% of NAV at 30 September ) and Oxford Nanopore (8.9%). Ireland-based but Nasdaq-listed Prothena  […]

12 Dec 2017

Baillie Gifford-favourite Alnylam completes key US filing

Baillie Gifford-favourite Alnylam completes key US filing US biotech star and Baillie Gifford stock pick Alnylam Pharmaceuticals has completed its US regulatory application for patisiran, a treatment of adults with hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis), putting the so-called RNA interference or “gene-silencing” therapeutic on track for approval in mid 2018.  Patisiran may become Alnylam’s first […]

12 Dec 2017

UK CAR-T firm Autolus provides update at ASH conference

UK CAR-T firm Autolus provides update at ASH conference Autolus, which is a closely-watched chimeric antigen receptor T-cell therapy firm backed by three of the UK’s most prominent biotech investors, obtained an important validation of its technology recently with the publication of data on its dual targeting technology at the American Society of Hematology (ASH) conference over […]

11 Dec 2017

Scottish Mortgage to benefit from Denali IPO

Scottish Mortgage to benefit from Denali IPO – Baillie Gifford-managed Scottish Mortgage Investment Trust SMT looks set to receive a significant £85m windfall as a result of last week’s Nasdaq IPO of  Denali Therapeutics, a US-based biotech in which it invested in 2016. Baillie Gifford was the lead investors in Denali’s $130m Series B financing round, investing […]

11 Dec 2017

Gilead reassures with CAR-T therapy durability data

Gilead reassures with CAR-T therapy durability data – Leading US biotech and investment company favourite Gilead Sciences has reassured investors with an important clinical trial update for its high profile cancer therapy Yescarta, which was obtained via the $12bn purchase of Kite Pharmaceuticals earlier this year.  Longer follow-up data from 108 advanced lymphoma patients treated with Yescarta […]

08 Dec 2017

Gilead acquires Cell Design Labs to bolster CAR-T presence

Gilead acquires Cell Design Labs to bolster CAR-T presence Leading US biotech Gilead Sciences is to acquire privately-held Cell Design Labs in a structured buy out valued at to $567m, including the 12.2% shareholding it already holds as a result of its $12bn acquisition of Kite Pharmaceuticals earlier this year. The Kite deal propelled Gilead […]

08 Dec 2017

Alexion stock rises on reports of activist investor

Alexion stock rises on reports of activist investor – Stock in the US rare disease specialist Alexion Pharmaceuticals is up 6% this morning on reports that the famed New York-based activist hedge fund Elliot Management has taken a stake. Elliott has reportedly threatened to initiate a proxy battle potentially to replace the relatively new management team […]

08 Dec 2017

Edinburgh Worldwide gets new deputy managers

Edinburgh Worldwide gets new deputy managers – Following discussion between the board and managers, Edinburgh Worldwide has announced the appointment of Svetlana Viteva and Luke Ward as deputy portfolio managers with immediate effect. Svetlana and Luke are part of Baillie Gifford’s Global Discovery investment team which is headed by Douglas Brodie, the manager of Edinburgh Worldwide. This […]

08 Dec 2017

Isaly steps down from OrbiMed and Worldwide Healthcare Trust

Isaly steps down from OrbiMed and Worldwide Healthcare Trust Veteran US biotech analyst and OrbiMed Capital founder Samuel Isaly has stepped down from his role as Managing Partner and separately as a director of UK-listed Worldwide Healthcare Trust WWH, which is managed by OrbiMed alongside Biotech Growth Trust BIOG. Isaly will be replaced at the New […]

07 Dec 2017

FDA OK for Alexion’s Soliris in myasthenia gravis

FDA OK for Alexion’s Soliris in myasthenia gravis US approval for Alexion’s complement inhibitor Soliris in anti-acetylcholine receptor antibody-positive generalised myasthenia gravis could double the market for a product that is already selling $3bn/year, if some of the most optimistic sell-siders are to be believed. Soliris, which is famously one of, if not the, most […]

24 Nov 2017

JPEL fund sells Celerion

JPEL fund sells Celerion – JPEL Private Equity, which invests in a portfolio private equity funds, has announced that MTS Health Investors, LLC, a healthcare-focused private equity firm, announced that its portfolio company Celerion Holdings, Inc. is being sold to a partnership between Court Square Capital Partners and the Celerion management team, who will continue to own a minority interest in […]

28 Feb 2017

Cash drag holds back earnings at Primary Health Properties

Primary Health Properties says its EPRA NAV per share increased from 87.7p to 91.1p over the course of 2016. The dividend was raised from 5p to 5.125p. The first quarterly dividend of the new year has been set at 1.31pEPRA earnings per share were lower at 4.8p, down from 4.9p on the back of increased […]

25 Nov 2016

Worldwide Healthcare changes fee arrangements

Worldwide Healthcare says its net asset value total return was +21.2% over the six months ended 30 September, outperforming the benchmark, the MSCI World Health Care Index measured on a net total return, sterling adjusted basis, which returned +17.3%. The share price, with a total return of +24.4%, also outperformed the benchmark over this period. The discount as at 30 September […]

22 Nov 2016

BACIT’s sterling hedge limits benefits from sterling depreciation

BACIT has announced its interim results for the six months ended 30 September 2016. During the period, the company’s NAV total return was 4.82%, thereby underperforming the FTSE All-Share Index, which returned 12.85%. Reflecting a widening of the discount during the period, the company’s share price fell by 4.2%. The trust’s chairman, Jeremy Tigue, says […]

15 Nov 2016

Woodford investment trust gets Trump boost

The Woodford Patient Capital trust has enjoyed a 4 per cent boost to its NAV following the election of Donald Trump to the White House. The Woodford fund was among the top-10 investment trusts on the day after the US election, with many of the best performing being focussed on biotech. read more here

04 Aug 2016

Woodford Patient Capital beefs up board after disappointing H1

Woodford Patient Capital says its portfolio declined in value by 10.8 per cent over the first half of 2016 and the company’s shares ended the period at a modest discount of 3.1 per cent. Two new non-executive directors have been brought onto the Board following consultation with shareholders. The new non-executive directors have specific investment trust experience. […]

14 Jul 2016

Lazard World Trust gets mixed results from China

Lazard World Trust Fund reports that, for the year ended March 31st 2016, the fund’s Net Asset Value per share at the year-end was US$ 4.17 representing a total return of minus 8.04% since the prior year end. The fund’s benchmark, the MSCI All Country World Index, declined 4.3% over the same period while the fund’s reference […]

22 Mar 2016

Woodford Patient Capital suspends fund raising

Woodford Patient Capital has published its first set of results covering the period from incorporation through its launch in April last year and finishing on 31 December 2015. The net asset value of Woodford Patient Capital Trust ended the period at 97.38p per share (cum income), slightly below the issue price of 100p per share. […]

16 Dec 2015

A volatile year for Polar Capital Global Healthcare

Polar Capital Global Healthcare Growth & Income Trust has announced its annual results for the year ended 30 September 2015. In what was a volatile year for the trust, its NAV total return was 8.2% thereby modestly underperforming its benchmark, the MSCI Global Healthcare Index, which returned 9.6%. The discount to NAV narrowed by 2% […]

26 Nov 2015

Worldwide Healthcare hit by sector sell off

Worldwide Healthcare has published interim results covering the six months to the end of September 2015. Over this period the pharmaceutical and biotech sectors experienced a sell off as US politicians waded into price gouging allegations at some forms. Worldwide Healthcare’s benchmark index (MSCI World Health Care Index) fell by 9.7%. the total return on net […]

06 Oct 2015

Kuala takes stake in Intensity Therapeutics

The Board of Kuala Innovations Limited has announced that it has subscribed for a 3.5 per cent. interest in Delaware incorporated private company Intensity Therapeutics, Inc. The Company has subscribed for 250,000 Preferred Series A Shares of Intensity Therapeutics (“Subscription Shares”) at a price of US$2.00 per Subscription Share, for total cash consideration of US$500,000. […]

11 Sep 2015

Public Service Properties in talks to sell remaining assets

Public Service Properties has reported its interim results for the six months ended 30 June 2015. The NAV at 30 June 2015 was 49.1p. In March 2015 the Company completed the disposal of its investment in the UK healthcare sector with the sale of companies, businesses and assets at a gross sale value of approximately £34.5m […]

11 Aug 2015

Woodford Patient Capital unveils its portfolio

Woodford Patient Capital has published its first set of figures – interims covering the period from its launch until the end of June 2015. The net asset value at the end of the period was 101.86p and the share price 113.5p – putting it on a premium of 11.4%. The Board is planning to issue […]

11 May 2015

Polar Capital Global Healthcare thinking about its long term future

Polar Capital Global Healthcare interim results for the six months ended 31 March 2015 show the company’s net asset value total return was 19.1%, a good result but unfortunately 2.6% behind the MSCI All Countries World Index Healthcare Index. What’s more, the discount widened from 5.4% to 9.8% so the return to shareholders was even […]

23 Mar 2015

Public Service Properties down to handful of German assets

Public Service Properties has announced its results for the year ended 31 December 2014. These have in large measure been superseded by the sale of its UK care home market and ancillary businesses for cash on 4 March 2015 and the sale of three of its German care homes in November 2014 and January 2015. […]

16 Dec 2014

Polar Capital Global Healthcare hit by widening discount

Polar Capital Global Healthcare results for the year that ended on 30 September 2014 have been released. Over the year the fund underperformed its benchmark by 5.1%, generating a return on net assets of 19.7% vs. 24.8% for the MSCI ACWI/Healthcare Index. The shares moved from a premium of 1.8% to discount of 5.4% so […]

01 Dec 2014

InterMune helps drive good Worldwide Healthcare result

WWH : InterMune helps drive good Worldwide Healthcare result Worldwide Healthcare powered ahead over the six months ended 30 September as the net asset value delivered a total return of 16.8%. The rating stayed more or less the same so the return to shareholders was 16.2%. by contrast the benchmark index (MSCI World Health Care) returned 11.5% […]

03 Nov 2014

Public Service Properties selling assets in Germany

PSPI : Public Service Properties selling assets in Germany Public Service Properties has announced the sale of two care homes in Langen and Luzerath in Germany leased to Marseille Kliniken AG. They will get €13.4m in cash and will use €10.7m of the proceeds to pay down debt associated with their German investments – reducing the […]

Please review our cookie, privacy & data protection and terms and conditions policies and, if you accept, please select your place of residence and whether you are a private or professional investor.

You live in…

You are a…